FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling

Swati Bhattacharyya*, Zenshiro Tamaki, Wenxia Wang, Monique Hinchcliff, Paul Hoover, Spiro Getsios, Eric S. White, John Varga

*Corresponding author for this work

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Scleroderma is a progressive autoimmune disease affecting multiple organs. Fibrosis, the hallmark of scleroderma, represents transformation of self-limited wound healing into a deregulated self-sustaining process. The factors responsible for maintaining persistent fibroblast activation in scleroderma and other conditions with chronic fibrosis are not well understood. Toll-like receptor 4 (TLR4) and its damage-associated endogenous ligands are implicated in immune and fibrotic responses. We now show that fibronectin extra domain A (FnEDA) is an endogenous TLR4 ligand markedly elevated in the circulation and lesional skin biopsies from patients with scleroderma, as well as in mice with experimentally induced cutaneous fibrosis. Synthesis of Fn EDA was preferentially stimulated by transforming growth factor-β in normal fibroblasts and was constitutively up-regulated in scleroderma fibroblasts. Exogenous FnEDA was a potent stimulus for collagen production, myofibroblast differentiation, and wound healing in vitro and increased the mechanical stiffness of human organotypic skin equivalents. Each of these profibrotic FnEDA responses was abrogated by genetic, RNA interference, or pharmacological disruption of TLR4 signaling. Moreover, either genetic loss of FnEDA or TLR4 blockade using a small molecule mitigated experimentally induced cutaneous fibrosis in mice. These observations implicate the FnEDA-TLR4 axis in cutaneous fibrosis and suggest a paradigm in which aberrant FnEDA accumulation in the fibrotic milieu drives sustained fibroblast activation via TLR4. This model explains how a damage-associated endogenous TLR4 ligand might contribute to converting self-limited tissue repair responses into intractable fibrogenesis in chronic conditions such as scleroderma. Disrupting sustained TLR4 signaling therefore represents a potential strategy for the treatment of fibrosis in scleroderma.

Original languageEnglish (US)
Article number232ra50
JournalScience translational medicine
Volume6
Issue number232
DOIs
StatePublished - Apr 16 2014

Fingerprint

Toll-Like Receptor 4
Toll-Like Receptors
Fibrosis
Fibronectins
Skin
Fibroblasts
Ligands
Wound Healing
Myofibroblasts
Transforming Growth Factors
RNA Interference
Autoimmune Diseases
Collagen
Pharmacology
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bhattacharyya, Swati ; Tamaki, Zenshiro ; Wang, Wenxia ; Hinchcliff, Monique ; Hoover, Paul ; Getsios, Spiro ; White, Eric S. ; Varga, John. / FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. In: Science translational medicine. 2014 ; Vol. 6, No. 232.
@article{743e6cc8f19141bf926a24adb9be62e5,
title = "FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling",
abstract = "Scleroderma is a progressive autoimmune disease affecting multiple organs. Fibrosis, the hallmark of scleroderma, represents transformation of self-limited wound healing into a deregulated self-sustaining process. The factors responsible for maintaining persistent fibroblast activation in scleroderma and other conditions with chronic fibrosis are not well understood. Toll-like receptor 4 (TLR4) and its damage-associated endogenous ligands are implicated in immune and fibrotic responses. We now show that fibronectin extra domain A (FnEDA) is an endogenous TLR4 ligand markedly elevated in the circulation and lesional skin biopsies from patients with scleroderma, as well as in mice with experimentally induced cutaneous fibrosis. Synthesis of Fn EDA was preferentially stimulated by transforming growth factor-β in normal fibroblasts and was constitutively up-regulated in scleroderma fibroblasts. Exogenous FnEDA was a potent stimulus for collagen production, myofibroblast differentiation, and wound healing in vitro and increased the mechanical stiffness of human organotypic skin equivalents. Each of these profibrotic FnEDA responses was abrogated by genetic, RNA interference, or pharmacological disruption of TLR4 signaling. Moreover, either genetic loss of FnEDA or TLR4 blockade using a small molecule mitigated experimentally induced cutaneous fibrosis in mice. These observations implicate the FnEDA-TLR4 axis in cutaneous fibrosis and suggest a paradigm in which aberrant FnEDA accumulation in the fibrotic milieu drives sustained fibroblast activation via TLR4. This model explains how a damage-associated endogenous TLR4 ligand might contribute to converting self-limited tissue repair responses into intractable fibrogenesis in chronic conditions such as scleroderma. Disrupting sustained TLR4 signaling therefore represents a potential strategy for the treatment of fibrosis in scleroderma.",
author = "Swati Bhattacharyya and Zenshiro Tamaki and Wenxia Wang and Monique Hinchcliff and Paul Hoover and Spiro Getsios and White, {Eric S.} and John Varga",
year = "2014",
month = "4",
day = "16",
doi = "10.1126/scitranslmed.3008264",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "232",

}

FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. / Bhattacharyya, Swati; Tamaki, Zenshiro; Wang, Wenxia; Hinchcliff, Monique; Hoover, Paul; Getsios, Spiro; White, Eric S.; Varga, John.

In: Science translational medicine, Vol. 6, No. 232, 232ra50, 16.04.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling

AU - Bhattacharyya, Swati

AU - Tamaki, Zenshiro

AU - Wang, Wenxia

AU - Hinchcliff, Monique

AU - Hoover, Paul

AU - Getsios, Spiro

AU - White, Eric S.

AU - Varga, John

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Scleroderma is a progressive autoimmune disease affecting multiple organs. Fibrosis, the hallmark of scleroderma, represents transformation of self-limited wound healing into a deregulated self-sustaining process. The factors responsible for maintaining persistent fibroblast activation in scleroderma and other conditions with chronic fibrosis are not well understood. Toll-like receptor 4 (TLR4) and its damage-associated endogenous ligands are implicated in immune and fibrotic responses. We now show that fibronectin extra domain A (FnEDA) is an endogenous TLR4 ligand markedly elevated in the circulation and lesional skin biopsies from patients with scleroderma, as well as in mice with experimentally induced cutaneous fibrosis. Synthesis of Fn EDA was preferentially stimulated by transforming growth factor-β in normal fibroblasts and was constitutively up-regulated in scleroderma fibroblasts. Exogenous FnEDA was a potent stimulus for collagen production, myofibroblast differentiation, and wound healing in vitro and increased the mechanical stiffness of human organotypic skin equivalents. Each of these profibrotic FnEDA responses was abrogated by genetic, RNA interference, or pharmacological disruption of TLR4 signaling. Moreover, either genetic loss of FnEDA or TLR4 blockade using a small molecule mitigated experimentally induced cutaneous fibrosis in mice. These observations implicate the FnEDA-TLR4 axis in cutaneous fibrosis and suggest a paradigm in which aberrant FnEDA accumulation in the fibrotic milieu drives sustained fibroblast activation via TLR4. This model explains how a damage-associated endogenous TLR4 ligand might contribute to converting self-limited tissue repair responses into intractable fibrogenesis in chronic conditions such as scleroderma. Disrupting sustained TLR4 signaling therefore represents a potential strategy for the treatment of fibrosis in scleroderma.

AB - Scleroderma is a progressive autoimmune disease affecting multiple organs. Fibrosis, the hallmark of scleroderma, represents transformation of self-limited wound healing into a deregulated self-sustaining process. The factors responsible for maintaining persistent fibroblast activation in scleroderma and other conditions with chronic fibrosis are not well understood. Toll-like receptor 4 (TLR4) and its damage-associated endogenous ligands are implicated in immune and fibrotic responses. We now show that fibronectin extra domain A (FnEDA) is an endogenous TLR4 ligand markedly elevated in the circulation and lesional skin biopsies from patients with scleroderma, as well as in mice with experimentally induced cutaneous fibrosis. Synthesis of Fn EDA was preferentially stimulated by transforming growth factor-β in normal fibroblasts and was constitutively up-regulated in scleroderma fibroblasts. Exogenous FnEDA was a potent stimulus for collagen production, myofibroblast differentiation, and wound healing in vitro and increased the mechanical stiffness of human organotypic skin equivalents. Each of these profibrotic FnEDA responses was abrogated by genetic, RNA interference, or pharmacological disruption of TLR4 signaling. Moreover, either genetic loss of FnEDA or TLR4 blockade using a small molecule mitigated experimentally induced cutaneous fibrosis in mice. These observations implicate the FnEDA-TLR4 axis in cutaneous fibrosis and suggest a paradigm in which aberrant FnEDA accumulation in the fibrotic milieu drives sustained fibroblast activation via TLR4. This model explains how a damage-associated endogenous TLR4 ligand might contribute to converting self-limited tissue repair responses into intractable fibrogenesis in chronic conditions such as scleroderma. Disrupting sustained TLR4 signaling therefore represents a potential strategy for the treatment of fibrosis in scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=84899051032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899051032&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3008264

DO - 10.1126/scitranslmed.3008264

M3 - Article

C2 - 24739758

AN - SCOPUS:84899051032

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 232

M1 - 232ra50

ER -